MAPK3 and nasopharyngeal carcinoma: The specific ERK inhibitor selumetinib effectively suppressed phospho-ERK1/2 expression in S18 cells and profoundly inhibited NPC CSC marker CD44 expression in a dose-dependent manner (Figure 4d).